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Background: Ischemic hypoxic brain injury often causes irreversible brain damage. The lack of effective and widely
applicable pharmacological treatments for ischemic stroke patients may explain a growing interest in traditional
medicines. β-Asarone, which has significant pharmacological effects on the central nervous system (CNS), was used
in the prevention of cerebral ischemia in this paper.
Methods: The right middle cerebral artery occlusion model was used in the study. The effects of β-Asarone on
mortality rate, neurobehavior, grip strength, lactate dehydrogenase, glutathione content, Lipid peroxidation,
glutathione peroxidase activity, glutathione reductase activity, catalase activity, Na+-K+-ATPase activity and
glutathione S transferase activity in a rat model were studied respectively.
Results: β-Asarone significantly improved the neurological outcome after cerebral ischemia and reperfusion in
terms of neurobehavioral function in rats. Meanwhile, supplementation of β-Asarone significantly boosted the defense
mechanism against cerebral ischemia via increasing antioxidants activity related to lesion pathogenesis. Restoration of
the antioxidant homeostasis in the brain after reperfusion may help the brain recover from ischemic injury.
Conclusions: These experimental results suggest that complement β-Asarone is protective against cerebral ischemia in
specific way. The administration of β-Asarone could reduce focal cerebral ischemic/reperfusion injury. The Mechanism
of β-Asarone in protection of cerebral ischemia was via increasing antioxidants activity related to lesion pathogenesis.Background
Ischemic hypoxic brain injury often causes irreversible
brain damage. The cascade of events leading to neuronal
injury and death in ischemia includes the release of cyto-
kines and free radicals, and induction of inflammation,
apoptosis, and excitotoxicity [1]. Reperfusion of ischemic
areas could exacerbate ischemic brain damage through
the generation of reactive oxygen species. The lack of ef-
fective and widely applicable pharmacological treatments
for ischemic stroke patients may explain a growing inter-
est in traditional medicines.
Acorus tatarinowii Schott is native to Central Asia,
North America and Eastern Europe [2]. β-Asarone* Correspondence: lichangyuzj@126.com; guojianyou@126.com
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reproduction in any medium, provided the or(cis-2,4,5-trimethoxy-1-allyl phenyl), which can affect
the central nervous system (CNS) [3-6], is a major com-
ponent of Acorus tatarinowii Schott. β-Asarone could
pass the blood–brain barrier (BBB) and thus enter the
brain [7]. It has been reported that β-Asarone (Figure 1)
could attenuate neuronal apoptosis in rat hippocampus
and might be a potential candidate for development as a
therapeutic agent to manage cognitive impairment asso-
ciated with conditions such as Alzheimer’s disease [8,9].
Other authors found β-Asarone could reduce the tox-
icity of excitatory amino acids and increase the expres-
sion of c-fos in the epileptic rat brain [10]. In addition,
β-Asarone could reduce the injuries of blood vessel
endothelium and nerve cells of the cortex [11] and im-
prove the cognitive function of the beta-amyloid hippo-
campus injection rats [12].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The chemical structure of β-Asarone.
Table 1 Effect of β-Asarone on basal grip strength
Different groups Grip strength
(Kg Units)
F-values df-values p-values
MCAO group 0.506 ± 0.002b
SHAM group 0.888 ± 0.008a 0.155 11 0.002
β-Asarone-10 group 0.560 ± 0.022b 0.154 11 0.005
β-Asarone-20 group 0.788 ± 0.004a 0.145 11 0.001
β-Asarone-30 group 0.799 ± 0.020a 2.974 11 0.004
Values are shown as means ± SEM. The different letters in the same column
indicate a statistical difference (p < 0.01 vs. MCAO group).
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effect of against ischemia-induced brain infarction. The
present study was aimed to investigate the effects of
β-Asarone on mortality rate, neurobehavior, grip strength,
lactate dehydrogenase, glutathione content, Lipid Peroxi-
dation, glutathione peroxidase activity, glutathione reduc-
tase activity, catalase activity, Na+-K+-ATPase activity and
glutathione S transferase activity in a rat model.Methods
Animals
Healthy adult Wistar rats (2 months old and weighing
225 ± 25 g) were used in the study. This study was ap-
proved by Zhejiang Chinese Medical University’s ethics
committee, and all procedures complied with the guid-
ance set out in the Guidelines for Caring for Experimen-
tal Animals published by the Ministry of Science and
Technology of the People’s Republic of China. Every care































Figure 2 Effect of β-Asarone on the development of behavioral
abnormalities after middle cerebral artery occlusion. Values are
shown as means ± SEM. *p < 0.05 vs. MCAO group, **p< 0.01 vs. MCAO
group. (FSHAM =17.642, dfSHAM=11, pSHAM=0.001, Fβ-Asarone−10=2.252, dfβ-
Asarone−10=11, pβ-Asarone−10=0.162, Fβ-Asarone−20=16.396, dfβ-Asarone−20=11,
pβ-Asarone-20 = 0.01, Fβ-Asarone−30=22.738, dfSHAM=11, pSHAM=0.02).Chemicals
Acorus tatarinowii Schott were collected in Bozhou,
China. Dr. Changyu Li at the Zhejiang Chinese Medical
University established the identity of these species.
β-Asarone was obtained as reported by Zanoli et al. [13].
Purity up to 99.55% was confirmed by gas chromatog-
raphy–mass spectrometry (GC-MS), infrared spectrum
(IR) and nuclear magnetic resonance (NMR) detection.
The voucher specimen (No. SAC/20120412) was depos-
ited at the Herbarium of the College of Pharmacology,
Zhejiang Chinese Medical University, China.
Experimental design
The animals were separated into five groups of ten rats
each. The first group served as sham (SHAM). The sec-
ond group was the ischemic group (MCAO). Group I
and group II were treated orally by distilled water for
30 days respectively. Group III (β-Asarone−10), Group
IV (β-Asarone−20) and Group V (β-Asarone−30) were
treated orally by β-Asarone (10, 20 and 30 mg/kg/day,
respectively) for 30 days followed by middle cerebral ar-
tery occlusion (MCAO) induced cerebral ischemia.
The right MCAO was performed using an intraluminal
filament model and the method described by Liu et al.
[14]. In brief, the rats were anesthetized with chloral hy-
drate (400 mg/kg, i.p.), a 4-0 nylon monofilament with a
blunt end was introduced into the external carotid artery
(ECA) and advanced into the middle cerebral artery via
the internal carotid artery (ICA) (17-20 mm), until a
slight resistance was felt. Successful occlusion was con-
firmed by an 87-90% reduction in cerebral blood flow
(CBF), as measured by laser-Doppler flowmetry [15].Table 2 Effect of β-Asarone on serum LDH levels
Different groups LDH (IU/L) F-values df-values p-values
MCAO group 156.200 ± 3.331
SHAM group 80.200 ± 1.233*** 6.555 5.183 0.000
β-Asarone-10 group 166.600 ± 2.111 7.190 11 0.118
β-Asarone-20 group 126.630 ± 3.111** 7.490 5.063 0.001
β-Asarone-30 group 111.231 ± 2.111** 0.425 11 0.005
Values are shown as means ± SEM. **p <0.01 vs. MCAO group, ***p <0.001 vs.
MCAO group.











2.398 ± 0.013** 7.993 6.286 0.009
β-Asarone-
10 group
1.115 ± 0.005 1.860 11 0.379
β-Asarone-
20 group
2.565 ± 0.015** 6.536 6.400 0.008
β-Asarone-
30 group
1.333 ± 0.002* 2.965 11 0.025
Values are shown as means ± SEM. *p <0.05 vs. MCAO group, **p < 0.01 vs.
MCAO group.
Table 5 Effect of β-Asarone on LPO level
Different groups nmol LPO/g
protein
F-values df-values p-values
MCAO group 20.21 ± 1.41
SHAM group 13.23 ± 0.66** 5.254 6.996 0.003
β-Asarone-10
group
20.01 ± 0.21 19.460 5.010 0.846
β-Asarone-20
group
15.32 ± 0.11* 1.304 10 0.043
β-Asarone-30
group
15.22 ± 0.21* 1.305 10 0.042
Values are shown as means ± SEM. *p <0.05 vs. MCAO group, **p < 0.01 vs.
MCAO group.
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ment was slowly withdrawn and the animals were
returned to their cages for a period of 22 hours of reper-
fusion. Throughout the procedure, the body temperature
was maintained at 37°C, with a thermostatically con-
trolled infrared lamp. In sham rats, the ECA was surgi-
cally prepared for the insertion of the filament, but the
filament was not inserted. The final number of rats was
as follows: SHAM group n = 10; MCAO group n = 6;
β-Asarone-10 group n = 8; β-Asarone−20 group n = 8
and β-Asarone−30 group n = 9.Neurobehavioral test
The sensorimotor integrity was conducted to assess the
neurobehavior at 24 h after MCAO in rats [16]. Five
categories of motor neurological findings were scored: 0,
no observable deficit; 1, forelimb flexion; 2, forelimb
flexion and decreased resistance to lateral push; 3, fore-
limb flexion, decreased resistance to lateral push and
unilateral circling; 4, forelimb flexion, unable or difficult
to ambulate. Animals that showed the features of the
higher scores also showed all the features of the lower











1.823 ± 0.026* 4.193 11 0.017
β-Asarone-
10 group
1.195 ± 0.021 4.043 11 0.336
β-Asarone-
20 group
1.595 ± 0.053* 3.306 11 0.026
β-Asarone-
30 group
1.395 ± 0.011* 3.418 11 0.427
Values are shown as means ± SEM. *p <0.05 vs. MCAO group.Grip strength study
Grip strength in all the animals was measured for
evaluation of neuromuscular strength, as described by
Ali et al. [17]. The neuromuscular strength tests were
carried out between 9:00 a.m. to 4:00 p.m. under stand-
ard laboratory conditions.
Tissue preparation
After grip strength measurement, blood samples were
drawn from the tail vein from all the groups and serum
was separated for biochemical estimations. Thereafter,
the animals were sacrificed immediately and their brains
were taken out to dissect the hippocampus (HIP). Post-
mitochondrial supernatant (PMS) obtained from 10%
homogenate of tissue was used for the estimation of
various parameters related with oxidative stress.
Biochemical estimations
In serum, lactate dehydrogenase (LDH) was estimated
using a method described by Khan et al. [18]. The PMS
and HIP were used for the assay of glutathione (GSH)
content, Lipid peroxidation (LPO), glutathione peroxid-
ase (GPx) activity, glutathione reductase (GR) activity,
catalase (CAT) activity, Na+-K+-ATPase activity and
glutathione S transferase (GST) activity [19-24].
Statistical analysis
The data are expressed as mean ± SEM. Statistical
differences between means were determined by one-wayTable 6 Effect of β-Asarone on the activity of GPx
Different groups GPx F-values df-values p-values
MCAO 8.11 ± 0.42
SHAM 14.28 ± 1.23** 0.713 11 0.001
β-Asarone-10 group 9.11 ± 1.22 0.910 11 0.306
β-Asarone-20 group 12.06 ± 1.22** 3.556 11 0.006
β-Asarone-30 group 11.11 ± 1.21* 0.053 11 0.04
Values are shown as means ± SEM. *p < 0.05 vs. MCAO group, **p < 0.01 vs.
MCAO group.
Table 7 Effect of β-Asarone on the activity of GR
Different groups GR F-values df-values p-values
MCAO 20.80 ± 2.10
SHAM 35.22 ± 2.41** 0.953 11 0.006
β-Asarone-10 group 21.11 ± 2.12 0.03 11 0.954
β-Asarone-20 group 30.01 ± 2.12* 4.394 11 0.028
β-Asarone-30 group 25.22 ± 2.01* 4.929 11 0.048
Values are shown as means ± SEM. *p < 0.05 vs. MCAO group, **p < 0.01 vs.
MCAO group.
Table 9 Effect of β-Asarone on the activity of CAT
Different groups CAT F-values df-values p-values
MCAO 4.20 ± 0.03
SHAM 7.10 ± 0.03* 7.196 12 0.010
β-Asarone-10 group 5.77 ± 0.14 3.917 10 0.076
β-Asarone-20 group 6.70 ± 0.13* 6.977 11 0.02
β-Asarone-30 group 6.71 ± 0.33* 6.858 11 0.024
Values are shown as means ± SEM. *p < 0.05 vs. MCAO group.
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The values of P < 0.05 were considered as significant.
Results and discussion
In this study, the cerebroprotective effect of β-Asarone
on ischemic neuronal damage was clearly demonstrated
using focal ischemia model rats.
The behavioral tasks adopted in this study were
designed to assess impairments consistent with the
known functional architecture of the rat brain.
Twenty-four hours after MCAO in rats, neurological
deficit scores were significantly reduced in β-Asarone−
20 -treated rats and β-Asarone−30-treated rats. The
neurobehavior for the SHAM group was 0.9 (0.6-1.1),
the MCAO group was 3.7 (2.6-5.3), the β-Asarone−10
group was 3.0 (2.2-4.1), the β-Asarone−20 group was 1.2
(1.0-4.1) and the β-Asarone−30 group was 1.0 (1.0-3.0).
It is clear that the behavioral abnormality was signifi-
cantly developed in the MCAO group as compared with
the sham (Figure 2). In contrast, the β-Asarone−20 group
and β-Asarone−30 group significantly suppressed the de-
velopment of behavioral abnormality as compared with
the MCAO group (Figure 2).
The grip strength in the SHAM group was found to
be 0.888 ± 0.008 kg units. A significant decrease in
the grip strength was observed in the MCAO group
(0.506 ± 0.002), as compared to the sham rats (P < 0.01).
Both β-Asarone−20 and β-Asarone−30 treated rats
showed a significant increase in grip strength, as com-
pared to the MCAO group (P < 0.01) (Table 1).
Increasing evidence has indicated that ischemia/reper-
fusion occurs due to oxidative stress that may potentiateTable 8 Effect of β-Asarone on the activity of GST
Different groups GST F-values df-values p-values
MCAO 10.17 ± 1.10
SHAM 15.11 ± 1.20** 16.088 13 0.002
β-Asarone-10group 11.60 ± 1.07 9.946 10 0.680
β-Asarone-20 group 13.61 ± 1.98** 19.214 11 0.008
β-Asarone-30group 12.66 ± 1.80* 20.293 12 0.029
Values are shown as means ± SEM. *p < 0.05 vs. MCAO group, **p < 0.01 vs.
MCAO group.ischemic injury [25]. Lactate dehydrogenase was mea-
sured to evaluate the role of antioxidative stress in the
protection of β-Asarone. The serum LDH levels in
SHAM group were found to be 80.200 ± 1.233 IU/L. A
significant increase in the activity of LDH in serum was
observed in MCAO group, as compared to the SHAM
group; whereas, β-Asarone−20 and β-Asarone−30 treat-
ment significantly resulted in decreased serum LDH
levels when compared with MCAO group rats (Table 2).
Reduced glutathione (GSH) is one of the primary en-
dogenous antioxidant defense systems in the brain,
which removes hydrogen peroxide and lipid peroxides.
Decline in GSH levels could either increase or reflect
oxidative status [26,27]. Concentrations of GSH were
lower in MCAO group than those in SHAM group
(Tables 3 and 4). β-Asarone−20 treatment significantly
increased the GSH.level. The same results did occur in
the β-Asarone−30 group. It can be attributed to several
factors such as cleavage GSH to cysteine, decrease in the
synthesis of GSH and the formation of mixed disulfides,
causing their cellular stores to be depleted [28].
The large numbers of polyunsaturated fatty acids make
cell membranes particularly vulnerable to lipid peroxida-
tion. The oxidation of polyunsaturated fatty acids alters
the structure of the membrane with resultant changes in
fluidity and permeability. Lipid peroxidation can also in-
hibit the function of membrane bound receptors and en-
zymes [29]. The level of LPO content adds to the proof
of the increased peroxidative damage during cerebral is-
chemia. A significant increase in the content of LPO was
observed in the MCAO group when compared with the
SHAM group. In the β-Asarone−20 and β-Asarone−30Table 10 Effect of β-Asarone on the activity of
Na+K+ATPase
Different groups Na+K+ATPase F-values df-values p-values
MCAO 2.11 ± 0.23
SHAM 4.53 ± 0.33** 16.966 11 0.002
β-Asarone-10group 2.00 ±0.11 0.176 11 0.684
β-Asarone-20 group 4.22 ±0.22* 17.700 11 0.001
β-Asarone-30group 4.16 ±0.33* 16.312 11 0.002
Values are shown as means ± SEM. *p < 0.05 vs. MCAO group, **p < 0.01 vs.
MCAO group.
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LPO when compared with the MCAO group (Table 5).
It has been proposed that antioxidant changes reflect
an altered redox balance in several pathological states.
The antioxidants would be consumed in the reaction
with free radicals. Therefore, the measurement of en-
dogenous antioxidants enzymes i.e. GPx, GR, CAT and
GST as well as Na+-K+-ATPase has been performed to
estimate the amount of oxidative stress. Activities of various
antioxidant enzymes and Na+-K+-ATPase of different
groups have been listed in Tables 6, 7, 8, 9 and 10. The ac-
tivity of endogenous antioxidant enzymes was decreased
significantly in the MCAO group, as compared to the sham
group, whereas in the β-Asarone−20 group, β-Asarone
-treatment showed a significant restoration in the level of
various enzymes as compared with MCAO group. The
same results did occur in the β-Asarone−30 group.
A great deal of effort has been directed toward
searching for a new drug that can be used for protection
of cerebral ischemia-reperfusion injury. β-Asarone was
used in the prevention of cerebral ischemia in this paper.
Here we showed that the β-Asarone significantly im-
proved the neurological outcome after cerebral ischemia
and reperfusion in terms of neurobehavioral function in
rats. At the same time, supplementation of β-Asarone
significantly boosted the defense mechanism against
cerebral ischemia by increasing antioxidants activity re-
lated to lesion pathogenesis. Restoration of the antioxi-
dant homeostasis in the brain after reperfusion may help
the brain recover from ischemic injury.Conclusions
These experimental results suggest that complement
β-Asarone is protective after cerebral ischemia in specific
way. The administration of β-Asarone significantly reduced
focal cerebral ischemic/reperfusion injury. The defense
mechanism against cerebral ischemia was by increasing an-
tioxidants activity related to lesion pathogenesis.
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